Faricimab
Treatment for Macular Degeneration
Typical Dosage: 6 mg intravitreal injection monthly for 4 doses, then extended up to every 16 weeks
Effectiveness
90%
Safety Score
45%
Clinical Trials
26
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
6 mg intravitreal injection monthly for 4 doses, then extended up to every 16 weeks
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$700
Side Effect Mgmt:$300
Total Annual:$11,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$85,000/QALY
QALYs Gained
0.85
Outcome-Based Costs
Cost per Responder
$11,827.96
Comparison vs Aflibercept
Cost Difference
$-2,000/year
Less expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Faricimab Outcomes
for Macular Degeneration
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+93%
Common Side Effects
Conjunctival hemorrhage
+15%
Eye pain
+8%
Vitreous floaters
+7%
Increased intraocular pressure
+3%
Endophthalmitis
+0.05%
Retinal detachment
+0.05%
Sources:
Active Clinical Trials
11 active trials recruiting for Faricimab in Macular Degeneration
Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.
NCT06271330RECRUITING
100 participants
OBSERVATIONAL
Nantes, France
Started: Apr 1, 2024
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
NCT06742307RECRUITINGPHASE4
40 participants
INTERVENTIONAL
Hong Kong, Hong Kong
Started: Aug 21, 2025
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
NCT06680817RECRUITING
850 participants
OBSERVATIONAL
Graz, Austria +53 more
Started: Feb 5, 2025
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients
NCT06572553RECRUITINGPHASE2, PHASE3
30 participants
INTERVENTIONAL
Hanzhou, China
Started: Mar 1, 2024
Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting
NCT07249216RECRUITINGNA
117 participants
INTERVENTIONAL
Singapore, Singapore
Started: Jul 18, 2025
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048ACTIVE NOT RECRUITINGPHASE4
274 participants
INTERVENTIONAL
Santa Ana, United States +67 more
Started: Mar 14, 2025
Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration
NCT07088445NOT YET RECRUITING
35 participants
OBSERVATIONAL
Started: Sep 1, 2025
Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals
NCT06875245RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Prague, Czechia
Started: Mar 31, 2023
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
NCT06439576ACTIVE NOT RECRUITING
1K participants
OBSERVATIONAL
Shantou, China +40 more
Started: May 9, 2024
Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
NCT06890026ACTIVE NOT RECRUITING
828 participants
OBSERVATIONAL
Glostrup Municipality, Denmark
Started: Nov 15, 2024
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
NCT07187804NOT YET RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Seoul, South Korea
Started: Sep 23, 2025
Completed Clinical Trials
9 completed trials for Faricimab in Macular Degeneration
Intravitreal Faricimab in Patients With Refractory Macular Edema
NCT07093385COMPLETEDPHASE2
43 participants
INTERVENTIONAL
Baghdad, Iraq
Started: Sep 10, 2024
Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab
NCT06231121COMPLETED
13 participants
OBSERVATIONAL
Glostrup Municipality, Denmark
Started: Dec 1, 2023
Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments
NCT06124677COMPLETED
46 participants
OBSERVATIONAL
Glostrup Municipality, Denmark
Started: Nov 1, 2023
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
NCT03823287COMPLETEDPHASE3
671 participants
INTERVENTIONAL
Phoenix, United States +160 more
Started: Feb 19, 2019
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
NCT03823300COMPLETEDPHASE3
658 participants
INTERVENTIONAL
Phoenix, United States +136 more
Started: Mar 11, 2019
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
NCT03038880COMPLETEDPHASE2
76 participants
INTERVENTIONAL
Phoenix, United States +24 more
Started: Jan 27, 2017
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
NCT05569148COMPLETEDPHASE3
35 participants
INTERVENTIONAL
Mesa, United States +2 more
Started: Oct 17, 2022
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT04777201COMPLETEDPHASE3
1.04K participants
INTERVENTIONAL
Mesa, United States +250 more
Started: Apr 19, 2021
Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration
NCT05941715COMPLETEDPHASE4
70 participants
INTERVENTIONAL
Graz, Austria
Started: Jul 4, 2023
Showing 20 of 27 total trials